The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
Saby GeorgeElizabeth J BellYing ZhengRuth KimJohn WhiteGeeta DevganJodi SmithLincy S LalNicole M Engel-NitzFrank X LiuPublished in: The oncologist (2021)
Patients taking immune checkpoint inhibitors (ICIs) who had adverse events (AEs) had significantly higher health care costs and utilization, driven by inpatient stays, compared with patients who did not. Given this high cost associated with AEs and the differences in the side effect profile of ICIs versus traditional chemotherapy, it is important for physicians to be cognizant of these differences when treating patients with ICIs. Ongoing evaluation, earlier recognition, and more effective, multidisciplinary management of AEs may improve patient outcomes and reduce the need for costly inpatient stays.
Keyphrases
- healthcare
- end stage renal disease
- palliative care
- newly diagnosed
- ejection fraction
- mental health
- primary care
- chronic kidney disease
- peritoneal dialysis
- cardiovascular events
- risk factors
- type diabetes
- squamous cell carcinoma
- radiation therapy
- coronary artery disease
- locally advanced
- social media
- chemotherapy induced